MeTA and data disclosure


Published on

Presentation by Samia Saad, MeTA Baseline Assessments Coordinator, during the MeTA country sharing meeting, London, December 2009.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

MeTA and data disclosure

  1. 1. <ul><li>Samia Saad: MeTA Baseline Assessments Coordinator </li></ul><ul><li>MeTA Country Sharing Meeting </li></ul><ul><li>London, 8 December 2009 </li></ul>MeTA & Data Disclosure
  2. 2. OUTLINE <ul><li>1. What does &quot; disclosure &quot; mean within the MeTA hypothesis </li></ul><ul><li>2. Disclosure as part of the Baseline  </li></ul><ul><li>Overview of disclosure Process in MeTA Countries </li></ul>
  3. 3. 1. Responsibility for access <ul><li>Governments are responsible for providing access to health care, including access to essential medicines </li></ul>
  4. 4. 2. Role of transparency <ul><li>Stronger and more transparent systems and improved supply chain management will increase access </li></ul>
  5. 5. 3. Equity <ul><li>Increasing equitable access to medicines improves health and enables other human development objectives to be achieved </li></ul>
  6. 6. 4. Evidence-based policy <ul><li>Improved information about medicines can inform public debate, and provide a basis for better policy </li></ul>6 Source WHO 2. Affordable prices ACCESS 1. Rational selection 4. Reliable health and supply systems 3. Sustainable financing
  7. 7. 5. Mutual accountability through mutli-stakeholder action <ul><li>A multi-stakeholder approach that involves all sectors – private, public and civil society - will lead to greater accountability </li></ul>7
  8. 8. Data Disclosure META Disclosure Transparency Improve Access to Medicines
  9. 9. How MeTA assists disclosure process <ul><li>Provides guidelines for a data set </li></ul><ul><li>Baseline studies in pilot countries in collaboration with Harvard Medical School, WHO, and the Institute for Development Studies at Sussex University </li></ul><ul><li>Provide tools, technical assistance, and additional resources to country groups to assist them in assembling existing pharmaceutical sector data, cataloguing key areas of data disclosure, synthesising information for priority setting, and producing concise summary country reports </li></ul>
  10. 10. Assisting the data disclosure process - objectives <ul><li>To provide robust and validated data and information for consideration, assessment and evaluation by the 3 stakeholder groups at the Meta Council, the result of which may lead to changes in government health policy and increases in access to essential medicines </li></ul><ul><li>The tools and methodologies developed in this process will be made available by MeTA in the public domain and may be applied by any countries who may wish to implement the MeTA process at a future date </li></ul>
  11. 11. <ul><li>Commitment by MeTA pilot countries as part of the MeTA core principles to disclose, analyze, and use over time data in the following four core areas: </li></ul><ul><ul><ul><li>1. Medicines registration and quality assurance </li></ul></ul></ul><ul><ul><ul><li>Availability of medicines </li></ul></ul></ul><ul><ul><ul><li>Price of medicines </li></ul></ul></ul><ul><ul><ul><li>4. Policies and practices concerning the promotion of medicines </li></ul></ul></ul>Data Disclosure How does the 'Data Disclosure' fit in with our national MeTA projects?
  12. 12. Key data collected/disclosed in MeTA <ul><li>Quality and registration status </li></ul><ul><ul><li>Medicines, GMP plants, GDP wholesalers, Licensed outlets </li></ul></ul><ul><li>Price data of medicines </li></ul><ul><ul><li>Procurement prices (~ MSH Intl price indicator) </li></ul></ul><ul><ul><li>Retail prices private, public sector (~WHO/HAI methodology) </li></ul></ul><ul><ul><li>Components (tax, VAT, margins, profit etc) </li></ul></ul><ul><li>Availability ( for basket of essential medicines) </li></ul><ul><li>Promotion (being developed by MeTA partner- pilot in Jan 2010) </li></ul><ul><li>… for each area: </li></ul><ul><li>Policy </li></ul><ul><li>Practices </li></ul><ul><li>Outcomes? </li></ul>
  13. 13. Who should disclose what? <ul><li>Government : VAT, taxes, budget, selection, quantification, </li></ul><ul><li>Procurement agency : purchase & selling prices </li></ul><ul><li>DRA : quality and registration data, inspection, QC lab results </li></ul><ul><li>Private sector : prices, margins, availability, promotion codes of conduct </li></ul><ul><li>Civil society / academics : Availability (equity), Affordability, Rational use </li></ul>
  14. 14. <ul><ul><ul><li>Objective </li></ul></ul></ul><ul><ul><ul><li>Identify, describe and assess the disclosure status of key types of pharmaceutical sector information related to the MeTA transparency agenda </li></ul></ul></ul>Data Disclosure Survey
  15. 15. <ul><ul><li>Part of Component 1 of MeTA baseline data assessment: An inventory of existing pharmaceutical sector data that is then made publicly available </li></ul></ul><ul><ul><li>Objective - for Essential Medicines List (EML) or basket of 30-50 core medicines: </li></ul></ul><ul><ul><ul><li>Assess the current status of data disclosure in the four core MeTA categories </li></ul></ul></ul><ul><ul><ul><li>Disclose the currently available data in the four MeTA core categories </li></ul></ul></ul><ul><ul><ul><li>Identify where there are gaps in information </li></ul></ul></ul><ul><ul><li>Many MeTA country workplans include a review of existing data and studies. It is hoped that using the data disclosure tool will facilitate this process </li></ul></ul>KEY POINTS (I) Data Disclosure Survey
  16. 16. <ul><ul><li>Available data for the survey will likely come from one or two sources (often the Govt. drug regulatory authority) and household and healthcare facility surveys (where available) </li></ul></ul><ul><ul><li>Using the tool is not only about data collection and disclosure! </li></ul></ul><ul><ul><ul><li>Discussing disclosure is a key part of multi-stakeholder work in MeTA. Important that MeTA Secretariat staff and all MeTA Council members be involved in discussion process </li></ul></ul></ul><ul><ul><ul><li>Lessons learned from process as important as findings and actual data disclosed </li></ul></ul></ul>KEY POINTS (II) Data Disclosure Survey
  17. 17. <ul><ul><li>PROCESS as important as data </li></ul></ul><ul><ul><li>WHY? </li></ul></ul><ul><ul><li>Indicates how well the stakeholder group is working </li></ul></ul><ul><ul><li>Indicates how willing various stakeholders are to disclose information around medicines </li></ul></ul>KEY MESSAGE Data Disclosure Survey
  18. 18. <ul><li>In order that disclosure survey may assist the MeTA Council in setting further national workplan priorities before external evaluation of the global MeTA project takes place [January-March 2010] </li></ul><ul><ul><li>Aim to complete collection of available data + discussion of findings/analysis by Council 30th November 2009 </li></ul></ul><ul><ul><li>Further validation of data could be conducted by 31 December 2009, in collaboration with Int. MeTA Sec. + Harvard Pharmaceutical Policy Group </li></ul></ul>Suggested TIMELINES Data Disclosure Survey
  19. 19. MeTA Baseline Assessments
  20. 20. <ul><ul><li>All 7 countries involved in pilot phase of MeTA initiative now implementing their country workplans </li></ul></ul><ul><ul><li>Many country workplans include review of national pharmaceutical sector </li></ul></ul><ul><ul><li>Int. MeTA Sec. tasked to encourage and support countries to undertake a baseline situation analysis after launch of their workplan activities </li></ul></ul><ul><ul><li>Baseline Data will help the MeTA country multi-stakeholder groups to set their future priorities </li></ul></ul>Baseline -Introduction
  21. 21. <ul><ul><li>Baseline assessment undertaken in each country may vary to some extent depending on national situation and resources </li></ul></ul><ul><ul><li>Int. MeTA Sec. & WHO worked with WHO Collaborating Centre in Pharmaceutical Policy at Harvard University and the Institute for Development Studies (IDS) to develop tools, provide technical assistance and additional resources </li></ul></ul>Baseline Introduction cont.
  22. 22. Objective of Baseline track national progress Long term evaluation of outcomes Level of engagement of different stakeholders country-specific indicators
  23. 23. Suggested Baseline Assessment Components COMPONENT OBJECTIVE TOOL Component 1. Inventory of existing pharmaceutical sector data - that is then made publicly available <ul><li>Pharmaceutical Sector Scan Survey </li></ul><ul><li>Data Disclosure Survey </li></ul>Component 2. Indication of degree of community access to essential medicines - through healthcare facility and household surveys <ul><li>Household Survey </li></ul><ul><li>Health Facility Survey </li></ul>Component 3. Indication of quality of multi-stakeholder process - includes 360-degree assessment of existing levels of engagement Multi-stakeholder engagement & communication survey
  24. 24. <ul><li> </li></ul>Status of Baseline Assessments Component 1. Component 2. Component 3. Jan. 2010 Disclosure survey complete (7 countries) Pharma sector scan (Gh & Phil.) Jor. Kyrg., Peru, Ug., Za. 1st April 2010 Ug. (2008) Gh. & Phil . Jor. (ongoing) Ug, Ph. Kyrg., Jor.,Peru Phil., Za.
  25. 25. Overview MeTA Countries Data Disclosure Surveys
  26. 26. <ul><li>Process varied across MeTA countries </li></ul><ul><li>Collective MeTA Council Meetings (3) to discuss the key disclosed data (Jordan) </li></ul><ul><li>Consultant hired with national MeTA funds to collect data (Peru) </li></ul><ul><li>2. Most countries had some level of engagement from the MSG </li></ul><ul><li>3. An initial reaction by some MeTA country MSGs: disclosure survey 'imposed' on them by Int. MeTA Sec….some countries needed further justification </li></ul><ul><li>4. Common theme across countries - national Secretariat coordinators or technical advisors had to do a lot of chasing for data themselves </li></ul><ul><li>5. Most of data held by public institutions </li></ul><ul><li>6. Many countries- no 'culture' of transparency (public sector)! </li></ul>Disclosure Process in MeTA Countries
  27. 27. <ul><li>MeTA is a Voluntary Project </li></ul><ul><li>Most key stakeholders who hold official resources of data have limited time. </li></ul><ul><li>RED TAPE - laborious and time-consuming process of obtaining data. Data collectors need to know how to navigate the system. </li></ul><ul><li>Data may exist but is not easily available or obtainable. </li></ul><ul><li>Data may exist but it needs piecing together to make sense- lack of capacity within public institutions to analyse and present data on medicines. </li></ul><ul><li>Lack of good information systems. </li></ul><ul><li>Some key Data sources not easily accessible (fee needed to obtain data). </li></ul><ul><li>Official websites sometimes poor or data updated infrequently -hinder accessibility to published data. </li></ul><ul><li>Private sector data often opaque, not 'obliged' to provide data </li></ul>Key Challenges
  28. 28. Samia Saad - International Consultant (Coordinator) Email: Wilbert Bannenberg - Technical Director, Int. MeTA Sec. Email: Elodie Brandamir - Operations Director, Int. MeTA Sec. Email: Key Contacts - MeTA Baseline Assessments
  29. 29. Thank You for your attention!